In addition, from recent clinical trials, CD47 antagonists administered intravenously could cause serious clinical hematotoxicity, such as anemia and thrombocytopenia [35–37], so that it is pivotal to develop a localized delivery matrix that can co-load sorafenib and CD47 antagonist in an “all-in-one” manner and deliver them in a spatiotemporally regulated pattern [38, 39]. This evidence concerns the gene CD47 and anemia.